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Abstract
We developed a mathematical model of calcium (Ca) and phosphate (PO4) home-
ostasis in the rat to elucidate the hormonal mechanisms that underlie the regulation
of Ca and PO4 balance. The model represents the exchanges of Ca and PO4 between
the intestine, plasma, kidneys, bone, and the intracellular compartment, and the for-
mation of Ca-PO4-fetuin A complexes. It accounts for the regulation of these fluxes
by parathyroid hormone (PTH), vitamin D3, fibroblast growth factor 23 (FGF23), and
Ca2+-sensing receptors. Our results suggest that the Ca and PO4 homeostatic systems
are robust enough to handle small perturbations in the production rate of either PTH
or vitamin D3. The model predicts that large perturbations in PTH or vitamin D3
synthesis have a greater impact on the plasma concentration of Ca2+ ([Ca2+]p) than
on that of PO4 ([PO4]p); due to negative feedback loops, [PO4]p does not consistently
increase when the production rate of PTH or vitamin D3 is decreased. Our results also
suggest that following a large PO4 infusion, the rapidly exchangeable pool in bone acts
as a fast, transient storage PO4 compartment (on the order of minutes), whereas the
intracellular pool is able to store greater amounts of PO4 over several hours. More-
over, a large PO4 infusion rapidly lowers [Ca
2+]p owing to the formation of CaPO4
complexes. A large Ca infusion, however, has a small impact on [PO4]p since a signifi-
cant fraction of Ca binds to albumin. This mathematical model is the first to include
all major regulatory factors of calcium and phosphate homeostasis.
Key words: calcium, phosphate, PTH, vitamin D3, FGF23, homeostasis, mathematical
model.
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1 Introduction
Phosphate (PO4) plays a key role in metabolic pathways such as ATP hydrolysis, and in
transduction signals. Together with calcium (Ca), it is also one of the major constituents
of bone, where it is stored mostly in the form of hydroxyapatite (Ca10(PO4)6(OH)2). The
homeostatic regulation of PO4 is tightly coupled to that of Ca. In the present study, we
expanded the calcium homeostasis model that we previously built [32] to include phosphate
and to examine the impact of hormonal dysfunctions on PO4 and Ca balance.
The distribution of PO4 in the human body is as follows: ∼ 85% is found in bone
and teeth (as hydroxyapatite), ∼ 14% is present in tissues and cells (as phospholipids and
phosphoproteins), and the remainder is in the extracellular compartment [24]. In plasma,
half the phosphate is ionized (present as H2PO
−
4 and HPO
2−
4 ), 40% forms complexes with
other ions such as Ca2+, Na+, and Mg2+, and the last 10% is bound to proteins [24, 49]. All
but the protein-bound forms are freely filtered by the kidney.
PO4 crosses the intestinal barrier via paracellular and transcellular pathways [29, 54].
About 70% of ingested PO4 is absorbed, mainly in the duodenum and jejunum in rats
[79]. On a low PO4 diet, the transcellular route predominates, whereas on a high PO4 diet,
paracellular transport prevails. Intestinal cells express the PO4 transporters Pit1, Pit2, and
NaPi-IIb. Pit transporters belong to the Type III sodium-phosphate co-transporters also
known as SLC20, whereas NaPi-IIb is a Type II sodium-phosphate co-transporter (SLC34).
NaPi-IIb mediates 90 % of transcellular absorption [69]. The regulation of PO4 absorption
by vitamin D3 is thought to happen mainly in the jejunum [54, 67].
In the kidney, 70-80% of the filtered load of PO4 is reabsorbed in the proximal tubule
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[79], mostly (∼ 80%) via the cotransporter NaPi-IIa (SLC34A1), but also via NaPi-IIc
(SLC34A3). About 10% is reabsorbed in the distal tubule, but the nature of the trans-
porter(s) involved has yet to be discovered [8]. In the proximal tubule, PO4 reabsorption is
negatively regulated by parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23),
and PO4 itself [42, 73]. Whether it is also dependent on vitamin D3 remains unclear [29].
FGF23 is an important regulator of PO4 homeostasis. It inhibits PO4 reabsorption
along the proximal tubule by reducing the expression of NaPi-IIa [5]. FGF23 also regulates
the metabolism of vitamin D3 [15, 73]; overexpression of FGF23 triggers the suppression
of vitamin D3 synthesis [15]. Consequently, FGF23-null mice exhibit hyperphosphatemia
and increased vitamin D3 levels. In addition, their bone turnover is decreased, for reasons
that remain unclear [41]. Conversely, vitamin D3 is the main systemic regulator of FGF23
production. VDR-null mice have undetectable levels of FGF23 [55].
PTH also acts to enhance the transcription of FGF23 [56], but it is possible that its effects
are mediated by vitamin D3 [4, 55]. Several studies suggest that FGF23 in turn affects the
synthesis and secretion of PTH, in part via MAPK signaling pathways [4]. Intravenous
injections of FGF23 decrease the gene expression and secretion of PTH in vitro [45], and
FGF23 inhibits PTH secretion in vivo, but other studies suggest a stimulatory effect of
FGF23 on PTH synthesis, perhaps owing to confounding factors [55]. In addition, FGF23
increases the expression of the calcium-sensing receptor (CaSR) and the vitamin D3 receptor
in parathyroid glands, and thereby plays a hypocalcemic role [13].
The mechanisms that regulate the plasma levels of Ca and PO4 are highly interrelated
and involve multiple feedback loops, as summarized in Figure 1. The goal of this study was
to develop a mathematical model of calcium and phosphate homeostasis in the rat so as
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to gain a better understanding of this complex regulatory network. There have been a few
published models of Ca and PO4 regulation in humans [61, 65, 66]; however they do not
incorporate the binding of Ca2+ and PO4 to each other and to other ions in plasma, the
presence of complexation inhibitors such as fetuin-A, and the multiple effects of FGF23 on
calcium and phosphate fluxes.
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2 Mathematical Model
Our model of calcium and phosphate homeostasis is based on conservation equations that
yield the plasma concentration of Ca, PO4, PTH, vitamin D3 and FGF23, as well as calcium
and phosphate fluxes between the compartments considered here. Model parameters apply
to a male rat weighing about 300 g (i.e.,∼ 2 month old), and can be modified to account for
sex- and age-based differences.
2.1 Phosphate species in plasma
The plasma concentration of total phosphate is ∼ 3 mM in the rat. Phosphate has two
dissociable protons: the H2PO
−
4 /HPO
2−
4 pair has a pKA of 6.8, and the HPO
2−
4 /PO
3−
4 pair
has a pKA of 12.3. The concentration of PO
3−
4 in plasma is thus negligible. We denote by
PO4 the sum of HPO
2−
4 and H2PO
−
4 , and by α and β, respectively, the HPO
2−
4 :PO4 and
H2PO
−
4 :PO4 ratios at a given plasma pH. At pH 7.4, α = 0.8 and β = 0.2; in other words,
HPO2−4 is 4 times more abundant than H2PO
−
4 in plasma.
2.1.1 Phosphate binding to Na+
Sodium-phosphate complexes, namely NaHPO−4 and NaH2PO4, account for a significant
fraction of total plasma phosphate (see below). The corresponding formation reactions are:
Na+ +HPO2−4
k
NaHPO−4
f
⇀↽
k
NaHPO−4
d
NaHPO−4 (1)
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Na+ +H2PO
2−
4
kNaH2PO4f
⇀↽
kNaH2PO4d
NaH2PO4 (2)
The equilibrium association constants are taken as, respectively, 4.70 ×10−3 mM−1 and 2.94
×10−3 mM−1 [57]. If we assume that kNaH2PO4d and kNaHPO
−
4
d are 10
5 s−1 (1666.7 min−1), then
k
NaHPO−4
f and k
NaH2PO4
f are respectively equal to 7.84 mM
−1.min−1 and 4.9 mM−1.min−1.
NaH2PO4 and NaHPO
−
4 form an acid/base pair with a pKA of 7.2:
NaHPO−4 +H
+
k
NaHPO−4
+
⇀↽
kNaHPO4−
NaH2PO4 (3)
Let NaPO4 denote the sum of NaHPO
−
4 and NaH2PO4, and γ and δ denote, respectively,
the NaHPO−4 :NaPO4 and NaH2PO4:NaPO4 ratios. At pH 7.4, γ = 0.62 and δ = 0.38.
The dynamics of NaPO4 complexes is governed by the following equations:
d[NaHPO−4 ]p
dt
= k
NaHPO−4
f [Na
+]p[HPO
2−
4 ]p − kNaHPO
−
4
d [NaHPO
−
4 ]p
−kNaPO4+ [NaHPO−4 ][H+] + kNaPO4− [NaH2PO4]
(4)
and
d[NaH2PO4]p
dt
= kNaH2PO4f [Na
+]p[H2PO
−
4 ]p − kNaH2PO4d [NaH2PO4]p
+kNaPO4+ [NaHPO
−
4 ]p[H
+]p − kNaPO4− [NaH2PO4]p
(5)
By summing these equations we obtain:
d[NaPO4]p
dt
= (αk
NaHPO−4
f + βk
NaH2PO4
f )[Na
+]p[PO4]p
−(γkNaHPO−4d + δkNaH2PO4d )[NaPO4]p
(6)
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To simplify notations, we define kNaPO4f = αk
NaHPO−4
f +βk
NaH2PO4
f and k
NaPO4
d = γk
NaHPO−4
d +
δkNaH2PO4d , and rewrite Eq. 6 as:
d[NaPO4]p
dt
= kNaPO4f [Na
+]p[PO4]p − kNaPO4d [NaPO4]p (7)
If [Na+]p is ∼ 140 mM, the steady-state plasma concentration of NaPO4 is estimated as:
[NaPO4]p =
kNaPO4f
kNaPO4d
[Na+]p[PO4]p ≈ 1 mM
which is about 30% of total plasma phosphate.
2.1.2 Formation of CaHPO4 and CaH2PO
+
4 salts
The mechanisms by which phosphate and calcium bind to each other are crucial to bone
formation. In plasma, they are tightly controlled by inhibitors of aggregation such as fetuin-
A. Ca2+ reacts with HPO2−4 and H2PO
−
4 as follows:
Ca2+ +HPO2−4
kCaHPO4f
⇀↽
kCaHPO4d
CaHPO4
Ca2+ +H2PO
−
4
k
CaH2PO
+
4
f
⇀↽
k
CaH2PO
+
4
d
CaH2PO
+
4
The equilibrium constants (based on ion activity) of the first and second reactions are
taken as 74 M−1 and 8 M−1 at 37◦C [52, 83]. Assuming that the steady-state plasma concen-
trations of Ca2+, HPO2−4 , and H2PO
−
4 at pH 7.4 equal 1.2, 1.28, and 0.32 mM, respectively,
those of CaHPO4 and CaH2PO
+
4 are estimated (using the same approach as above) as 0.11
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and 0.003 mM, respectively. Note that the plasma concentration of CaHPO4 is about 10%
that of Ca2+. In the dynamic model, we do not assume instant equilibrium between these
species. Instead, we fix the value of kCaHPO4d and k
CaH2PO
+
4
d at 1666.7 min
−1. With this
assumption, we have k
CaHPO2−4
f = 127.4 mM
−1.min−1 and kCaHPO
2−
4
f = 13.7 mM
−1.min−1.
If in a given compartment the concentration of calcium-phosphate salts reaches a certain
threshold, precipitation occurs and insoluble crystals form. The main crystalline species
found in bone are hydroxyapatite (Ca10(PO4)6(OH)2), dicalcium-phosphate-dihydrate or
brushite (CaHPO4.2H2O), and octacalcium-phosphate (Ca8H2(PO4)6.5H2O). Whether pre-
cipitation occurs depends on the supersaturation S of the system:
S =
IP
Ksp
, (8)
where IP is the ionic product and Ksp is the constant of solubility. Below saturation (S < 1),
there is no crystal formation. Above saturation (S > 1), the Ca-PO4 complexes form a solid
precipitate. The ionic product is given by:
IP =
nT∏
([xi]fzi)
ni . (9)
where nT is the total number of ions that form the complex, [xi] is the concentration of ion
i and ni is the stoichiometric coefficient of i. The activity coefficient (denoted fzi below)
depends on the valence zi of i as well as the ionic strength I of the solution :
− log10(fzi) = A× z2i
( I1/2
1 + I1/2
− 0.3× I
)
(10)
I =
1
2
n∑
1
[xi]z
2
i (11)
where A is estimated as 0.52 at 37◦C [83]. Note that Eq. (10) can be used only if I ≤ 0.5 M;
in human and rat plasma, I is approximately equal to 0.16 M [27]. Substituting this value
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of I into Eq. (10), we obtain
fzi = 10
−0.12×z2i (12)
which yields f1 = 0.76, f2 = 0.33 and f3 = 0.08, respectively, for monovalent, divalent,
and trivalent ions. Since the plasma concentration of PO3−4 is negligible, the supersaturation
index of octacalcium-phosphate and hydroxyapatite in plasma remains well under the thresh-
old; that of brushite in plasma is estimated to be ∼ 0.9 under normal conditions (pH = 7.4,
[Ca2+]p= 1.2 mM, [HPO
2−
4 ]p = 1.3 mM, [Mg
2+]p= 1 mM, [HCO
−
3 ]p = 24 mM, and [Na
+]p=
142 mM). Note that in certain conditions, the threshold for saturation may be higher than
1; in urine, it is estimated as ∼ 10 [37]. In the model, the saturation threshold in plasma
and the rapidly exchangeable pool is taken as 1.5.
2.1.3 Degradation of CaHPO4 and CaH2PO
+
4 salts
In plasma, fetuin-A, a liver-derived blood protein, binds small clusters of calcium and phos-
phate to form complexes known as calciprotein particles [64, 84]. Since these nanoparticles
prevent crystal growth and aggregation, fetuin-A is a key inhibitor of mineralization. In the
absence of fetuin-A, vascular calcifications may appear [76]. We assume that the reaction
between fetuin-A and either CaHPO4 or CaH2PO
+
4 occurs in plasma only, and is a first-order,
irreversible kinetic process, characterized by the (same) reaction rate kfetAf . The dynamic
evolution of the plasma concentrations of CaHPO4 and CaH2PO
+
4 is expressed as:
d[CaHPO4]p
dt
= kCaHPO4f [Ca
2+]p[HPO
2−
4 ]p − kCaHPO4d [CaHPO4]p
−kfetAf [CaHPO4]p
(13)
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d[CaH2PO
+
4 ]p
dt
= k
CaH2PO
+
4
f [Ca
2+]p[H2PO
−
4 ]p − kCaH2PO
+
4
d [CaH2PO
+
4 ]p
−kfetAf [CaH2PO+4 ]p
(14)
Let CaPO4 denote the sum of CaHPO4 and CaH2PO
+
4 . Adding the two previous equa-
tions and incorporating the HPO2−4 :PO4 and H2PO
−
4 :PO4 ratios yields:
d[CaPO4]p
dt
= kCaHPO4f α[Ca
2+]p[PO4]p − kCaHPO4d [CaHPO4]p
+k
CaH2PO
+
4
f β[Ca
2+]p[PO4]p − kCaH2PO
+
4
d [CaH2PO
+
4 ]p
−kfetAf [CaPO4]p
(15)
The plasma concentration of calciprotein particles (CPP) is determined by:
d[CPP ]p
dt
= kfetAf [CaPO4]p − kCPPc [CPP ]p (16)
The second term on the right-hand side accounts for the degradation of CPP through the
reticuloendothelial system [38], which occurs over several minutes. The constant kCPPc is
taken as 3 min−1 [38]. Parameters related to PO4 and Ca complex formation are listed in
Table 1.
2.2 Phosphate homeostasis
2.2.1 Intestinal absorption of phosphate
We assume that net intestinal PO4 absorption (Γ
PO4
abs ) represents at most 70% of PO4 intake
(IPO4) [67], and that vitamin D3 modulates 3/7 of Γ
PO4
abs [36]. That is:
ΓPO4abs ([D3]p) = IPO4
(
0.4 +
0.3[D3]
2
p
[D3]2p + (K
D3
abs)
2
)
(17)
The parameter KD3abs is taken to be the same for calcium and phosphate.
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2.2.2 Intracellular phosphate
Intracellular phosphate can be bound or incorporated into the phospholipids of cell mem-
branes but most of it is in mitochondria. Assuming that PO4 fluxes between plasma and the
intracellular compartment obey first-order dynamics, we have:
dN cPO4
dt
= kpc[PO4]pVp − kcpN cPO4 (18)
where NcPO4 is the intracellular amount of total phosphate, kpc characterizes the rate of phos-
phate transport from plasma to cells, and kcp that from cells to plasma. To our knowledge,
N cPO4 has not been determined in rats and is therefore extrapolated from human data. In
adult humans, the intracellular and extracellular compartments respectively contain about
15% and 0.3 % of total body phosphate [79]; assuming that these fractions are the same in
rats, the quantity of intracellular phosphate in rats is estimated as 3 mmol.
2.2.3 Renal reabsorption of phosphate
The ionized and ion-bound forms of PO4, which represent about 90 % of total plasma
phosphate, are freely filtered by the kidney. In the absence of phosphate accumulation in
the kidney, the sum of fractional reabsorption (λPO4reab ) and fractional urinary excretion (λ
PO4
u )
is unity, that is:
λPO4u = 1− λPO4reab (19)
We assume that phosphate reabsorption occurs essentially in the proximal (PT) and distal
convoluted (DCT) tubules, such that:
λPO4reab = λ
PO4
PT + λ
PO4
DCT
(20)
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The fraction of PO4 that is reabsorbed in the distal tubule (λ
PO4
DCT ) is taken to be fixed
at 10%. In the proximal tubule, PO4 reabsorption (about 70-80 % of the filtered load) is
negatively regulated by PTH, FGF23, and high phosphate [42, 73]. The effects of vitamin
D3 on the renal transport of PO4 remains unclear [29] and are not considered here.
We therefore write λPO4PT as:
λPO4PT = λ
0
PT + δPT (PTHp) + δPT (FGFp) + δPT (PO4p) (21)
where
δPT (PTHp) =
δmaxPTH
([PTH]p/KPTHPT )
5 + 1
(22)
δPT (FGFp) =
δmaxFGF
([FGF ]p/KFGFPT )
5 + 1
(23)
δPT (PO4p) =
δmaxPO4
([PO4]p/K
PO4
PT )
5 + 1
(24)
We make the following assumptions: λ0PT is fixed at 55%; δ
max
FGF23 = 20%, δ
max
PTH = 10%,
and δmaxPO4 = 5%. The constants K
PTH
PT , K
FGF
PT , and K
PO4
PT are given in Table 2.
2.2.4 Phosphate in bone
The bone compartment is divided into a slowly exchangeable pool and a rapidly exchangeable
(fast) pool. The fast pool has yet to be fully characterized [10, 50, 53]. Its composition, and
the processes by which Ca and PO4 are transferred into/out of it, remain poorly understood
[62]. We respectively denote by NbPO4 and N
f
PO4
the amount of PO4 in the slow and fast pools.
NbPO4 varies according to the difference between the flux of PO4 into the slowly exchangeable
pool and the rate of PO4 resorption (denoted Γ
PO4
res ). Assuming that the former obeys first-
order kinetics (with a rate constant γPO4in ), we have:
dN bPO4
dt
= γPO4in N
f
PO4
− ΓPO4res (PTH,D3) (25)
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The PO4 resorption rate is determined as:
ΓPO4res (PTH,D3) =
[
Γminres,PO4 + δ
max
res,PO4
(
0.20× [PTH]
2
p
[PTH]2p + (K
PTH
res )
2
+ 0.80× [D3]
2
p
[D3]2p + (K
D3
res)2
)]
(26)
The dependence of ΓPO4res on PTH and vitamin D3 is taken to be the same as that of the Ca
resorption rate.
In the rapidly exchangeable pool, we distinguish between the different forms of unbound
and bound PO4, that is, between HPO
2−
4 , H2PO
−
4 , CaHPO4, and CaH2PO
+
4 . The total
amount of PO4 in this compartment varies with the rates of PO4 exchange between plasma
and the rapid pool, the PO4 flux into the slow pool, and complexation reactions, such that:
dN fPO4
dt
= kPO4pf [PO4]pVp − kPO4fp N fPO4 − γPO4in N fPO4 −
dN fCaHPO4
dt
− dN
f
CaH2PO4+
dt
(27)
where kPO4pf characterizes the rate of PO4 transport from plasma to the fast pool, and k
PO4
fp
that from the fast pool to plasma. Assuming that the HPO2−4 :PO4 and H2PO
−
4 :PO4 ratios
in the rapidly exchangeable bone pool are equal to those in plasma (respectively, α and β),
the conservation equations for the CaHPO4 and CaH2PO
+
4 complexes in the rapid pool are
written as:
dN fCaHPO4
dt
= kCaHPO4f αN
f
Ca2+N
f
PO4
− kCaHPO4d (28)
and
dN fCaH2PO4+
dt
= k
CaH2PO
+
4
f βN
f
Ca2+N
f
PO4
− kCaH2PO+4d (29)
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2.2.5 Phosphate in plasma
Assuming that the amount of PO4 that is bound to Mg
2+ is negligible [85], the conservation
of total PO4 in plasma can be expressed as:
d[POtot4 ]p
dt
=
d[PO4]p
dt
+
d[CaPO4]p
dt
+
d[NaPO4]p
dt
+
d[CPP ]p
dt
(30)
The total amount of PO4 in plasma varies according to PO4 exchanges between plasma
and intestine, bone, cells, kidney, and macrophages, such that:
d[POtot4 ]p
dt
=
1
Vp
{
ΓPO4abs (D3) + Γ
PO4
res (PTH,D3)− kPO4pf [PO4]pVp + kPO4fp N fPO4
+kcpN
c
PO4
− kpc[PO4]pVp
−λPO4u GFR([PO4]p + [CaPO4]p + [NaPO4]p)
}
−kCPPc [CPP ]p
(31)
where GFR denotes the glomerular filtration rate. Combining Eqs. (15), (30) and (31), we
Page 14
obtain:
d[PO4]p
dt
=
1
Vp
{
ΓPO4abs (D3) + Γ
PO4
res (PTH,D3)− kPO4pf [PO4]pVp + kPO4fp N fPO4
+kcpN
c
PO4
− kpc[PO4]pVp
−λPO4u GFR([PO4]p + [CaPO4]p + [NaPO4]p)
}
−kNaPO4f [Na+]p[PO4]p + kNaPO4d [NaPO4]p
−kCaHPO4f α[Ca2+]p[PO4]p + kCaHPO4d [CaHPO4]p
−kCaH2PO+4f β[Ca2+]p[PO4]p + kCaH2PO
+
4
d [CaH2PO
+
4 ]p
(32)
Parameters related to PO4 homeostasis are summarized in Table 2.
2.3 Ca homeostasis
In plasma, about 50% of Ca is bound to proteins, albumin being the dominant ligand (46-
55%) [7, 88]. We previously assumed that the fraction (κb) of Ca bound to proteins such
as albumin remains constant [32]. In the present model, we explicitly take into account the
dynamic binding of Ca2+ to albumin. Note that since there are no quantitative data on PO4
binding to proteins (especially to albumin), and since the fraction of PO4 bound to proteins
is only 10 % of total phosphate, we do not consider the dynamic binding of phosphate to
albumin.
Let Alb2− denote the free Ca2+ binding sites on the albumin molecule and CaAlb the
number of bound sites. The binding of Ca2+ to albumin binding can be represented as
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follows:
Ca2+ + Alb2−
kCaAlbf
⇀↽
kCaAlbd
CaAlb, (33)
At pH 7.4, the association constant is estimated as 0.11 mM−1 [26]. Assuming that kCaAlbd =
1666.7 min−1, then kCaAlbf = 190.2 mM
−1.min−1. We assume that the total concentration of
albumin in plasma ([Albtot]p) is constant and equal to 0.36 mM [88], and that the number of
available binding sites per albumin molecule (NAlb) is equal to 20 at pH 7.4 [26]. We have:
NAlb × [Albtot]p = [Alb2−]p + [CaAlb]p ⇐⇒ [Alb2−]p = NAlb × [Albtot]p − [CaAlb]p
The conservation equation for the calcium-albumin complex is then written as:
d[CaAlb]p
dt
= kCaAlbf [Ca
2+]p[Alb
2−]p − kCaAlbd [CaAlb]p
= kCaAlbf [Ca
2+]p(NAlb[Alb
tot]p − [CaAlb]p)− kCaAlbd [CaAlb]p
(34)
At steady-state, the concentration of calcium bound to albumin is estimated as:
[CaAlb]p =
kCaAlbf
(kCaAlbd + k
CaAlb
f [Ca
2+]p)
[Ca2+]p[Alb
tot]pNAlb = 0.85 mM (35)
Since the binding of Ca2+ to other plasma proteins (such as globulins) has not been
well characterized, we make the simplifying assumption that the latter have the same Ca2+
binding characteristics as albumin. That is, we assume that all plasma proteins (denoted
Prot) have the same association and dissociation constants, and the same number of binding
sites. If the total concentration of plasma proteins ([Prottot]p) is taken as 0.6 mM [88], the
plasma concentration of calcium-protein complexes at steady state is then estimated as:
[CaProt]p =
kCaProtf
(kCaProtd + k
CaProt
f [Ca
2+]p)
[Ca2+]p[Prot
tot]pNProt = 1.42 mM. (36)
Page 16
2.3.1 Conservation equation for plasma calcium
The conservation equation for total Ca in plasma can be written as:
d[Catot]p
dt
=
d[Ca2+]p
dt
+
d[CaProt]p
dt
+
d[CaPO4]p
dt
+
d[CPP ]p
dt
(37)
The total amount of Ca in plasma varies according to Ca exchanges between plasma and
intestine, bone, kidney, and macrophages, such that:
d[Catot]p
dt
=
1
Vp
{
ΓCaabs(D3) + Γ
Ca
res(PTH,D3)− kCapf [Ca2+]pVp + kCafpN fCa2+
−λCau GFR([Ca2+]p + [CaPO4]p)
}
−kCPPc [CPP ]p
(38)
where ΓCaabs is the rate of intestinal Ca
2+ absorption, ΓCares is the rate of Ca
2+ resorption, NfCa2+
is the amount of Ca2+ in the rapidly exchangeable pool, kCapf and k
Ca
fp characterize the rate of
Ca2+ exchanges between plasma and the rapid pool, and λCau denotes fractional Ca
2+ urinary
excretion. These functions and parameter values can be found in Ref. [32].
Combining Eqs. (15), (37) and (38), we obtain:
d[Ca2+]p
dt
=
1
Vp
{
ΓCaabs(D3) + Γ
Ca
res(PTH,D3)− kCapf [Ca2+]pVp + kCafpN fCa2+
−λCau GFR([Ca2+]p + [CaHPO4]p + [CaH2PO+4 ]p)
}
−kCaProtf [Ca2+]pNProt[Prottot]p + kCaProtd [CaProt]p
−kCaHPO4f α[Ca2+]p[PO4]p + kCaHPO4d [CaHPO4]p
−kCaH2PO+4f β[Ca2+]p[PO4]p + kCaH2PO
+
4
d [CaH2PO
+
4 ]p
(39)
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Given the coupling between the homeostasis of calcium and that of phosphate, the values of
several calcium-related parameters described in our previous model [32] had to be adjusted.
New parameters values are listed in Table 3.
2.4 Hormone conservation equations
2.4.1 FGF23 dynamics
In the following equations, FGF23 is denoted by FGF and its concentration in plasma by
[FGF ]p. In light of the uncertainties described above, we assume that the production of
FGF23 is directly modulated only by vitamin D3 and phosphate. The conservation of FGF23
is expressed as:
d[FGF ]p
dt
= kFGFprod (1 + δ
FGF
prod ×G1([D3]p)×G2([PO4]p))− kFGFdeg [FGF ]p (40)
The first term on the right-hand-side denotes the amount of FGF23 that has been gener-
ated in bone and transported into plasma; the coefficient kFGFprod represents the basal FGF23
synthesis rate. The second term represents the degradation of FGF23, with a rate constant
kFGFdeg taken as 0.013 min
−1 [87], consistent with its half life of 46-58 minutes [44]. The
modulation of FGF23 synthesis by vitamin D3 and PO4 is represented by:
G1([D3]p) =
[D3]
5
p
(KD3FGF )
5 + [D3]5p
(41)
G2([PO4]p) =
[PO4]p
KPO4FGF + [PO4]p
(42)
Assuming that δFGFprod equals 10, the FGF23 synthesis rate is multiplied by a factor of 11
relative to its basal value when both vitamin D3 and PO4 exert maximal effects. The
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constants KD3FGF and K
PO4
FGF are set to the equilibrium values of the plasma concentration
of vitamin D3 and PO4, respectively. Since we could not find experimental estimates of
kFGFprod , we estimated its value based on steady-state conditions, i.e., assuming that the basal
concentration of FGF23 in plasma is 17 pM [80].
2.4.2 Conservation of Vitamin D3
The active form of vitamin D3 (1,25(OH)2D3, or calcitriol) is synthesized in the proximal
tubule, where the conversion of its precursor (25-hydroxyvitamin D, denoted Dinact3 below) is
mediated by the enzyme CYP27B1. As described previously [32], we assume that this con-
version is activated by PTH with a delay τ of 4 hours, and is inhibited by Ca2+ and vitamin
D3 itself. The degradation of vitamin D3, which is catalyzed by the enzyme CYP24A1, is
also modulated by PTH and vitamin D3. The present model incorporates additional effects:
FGF23 and PO4 both inhibit CYP27B1, and FGF23 activates CYP24A1. The conservation
equation for vitamin D3 is therefore rewritten as:
d[D3]p
dt
=
[
kminconv +
δmaxconv([PTH]p(t− τ))6(
([PTH]p(t− τ))6 + (KPTHconv )6
) × KCaconvKD3conv(
[Ca2+]p +KCaconv
)(
[D3]p +K
D3
conv
)
× K
PO4
convK
FGF
conv(
[PO4]p +K
PO4
conv
)(
[FGF ]p +KFGFconv
)][Dinact3 ]p
−k
D3
deg(1 + γ
FGF
D3
[FGF ]p)[D3]p
1 + γPTHD3 [PTH]p
(43)
The first term within brackets on the right-hand-side represents the basal synthesis rate
of vitamin D3. The next term within brackets accounts for its activation by PTH and its
repression by Ca2+, vitamin D3, PO4, and FGF23. We assume that FGF23 and PO4 act
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independently, with respective affinities KFGFconv and K
PO4
conv . The last term represents the
degradation of vitamin D3, with sensitivity coefficients γ
FGF
D3
and γPTHD3 to FGF23 and PTH,
respectively.
2.4.3 Conservation equation for PTH
The current model accounts for the stimulation of PTH synthesis by PO4. Since the direct
effects of FGF23 on PTH synthesis remain to be clarified, they are not considered at this
stage. The conservation equation for PTH in the parathyroid gland (PTHg) is rewritten as:
d[PTH]g
dt
=
kPTHgprod K
D3
PTH [PO4]
3(
[D3]p +K
D3
PTH
)(
[PO4]3 + (K
PO4
PTH)
3
) − (kPTHgdeg + F ([Ca2+]p))[PTH]g (44)
The first term on the right-hand-side represents the rate of PTH synthesis, which is activated
by PO4 and inhibited by vitamin D3. The second term characterizes the rates of PTH
degradation and exocytosis. The function F , which characterizes the modulation of PTH
secretion by CaSR, is defined as follows:
F ([Ca2+]p) = β
PTHg
exo −
γ
PTHg
exo [Ca2+]
n(Ca)
p
[Ca2+]
n(Ca)
p +K
n(Ca)
Ca
(45)
The rate constants β
PTHg
exo and γ
PTHg
exo characterize, respectively, maximal PTH secretion
and its maximal modulation by CaSR; KCa represents the binding affinity of Ca
2+ to CaSR,
and the exponent n is given by:
n(Ca) =
nexo1
1 + e−ρexo(R−[Ca2+]p)
+ nexo2 (46)
nexo1 and n
exo
2 denote the sensitivity of CaSR to Ca
2+ under hypocalcemia and hypercal-
cemia, respectively, and R is the Ca2+ concentration threshold below which there is hypocal-
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cemia. The conservation equation for PTH in plasma (PTHp) remains unchanged:
d[PTH]p
dt
= F ([Ca2+]p)
Vc
Vp
[PTH]g − kPTHpdeg [PTH]p (47)
Parameters corresponding to the metabolism of PTH, vitamin D3, and FGF23 are re-
spectively listed in Tables 4, 5 and 6.
2.5 Sensitivity analysis
In the absence of experimental data, several parameter values had to be estimated, as spec-
ified in Tables 2 and 3. Production rates were determined based on concentration values at
steady-state. The affinity K (or its inverse γ) to a given solute was first taken to be equal to
the plasma concentration of that solute at steady-state, and subsequently adjusted to yield
expected behavior under different scenarios. Other parameter values were chosen to yield
the best fit to experimental data in Refs. [28, 33, 80].
We conducted a sensitivity analysis to assess the impact of uncertainties in the following
parameters: kCapf , k
Ca
fp , k
CaAlb
d , kpc, kcp, N
c
PO4
, kPO4pf , k
PO4
fp , k
NaHPO−4
d , k
NaH2PO4
d , k
CaHPO4
d ,
k
CaH2PO
+
4
d and kfet. The base-case value of each of these parameters was multiplied or
divided by a factor of 4, and the resulting steady-state values of [Ca2+]p, [PO4]p, [PTH]p,
[D3]p, and [FGF]p were then compared with their base-case values. Results are shown in
Table 7.
The predicted value of [Ca2+]p is most sensitive to variations in the rate constants that
characterize the Ca2+ fluxes between plasma and the rapidly exchangeable bone pool, i.e.,
kCapf and k
Ca
fp . The predicted [PO4]p is most sensitive to variations in k
CaHPO4
d and kfet, as
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well as kPO4pf and k
PO4
fp ; however, it is not substantially affected by the rates of PO4 exchange
between plasma and the intracellular pool (kpc and kcp). The predicted values of [PTH]p,
[D3]p, and [FGF]p are also impacted the most by variations in the rates of Ca
2+ and PO4
exchanges between plasma and the rapidly exchangeable pool. Changes in the remaining
parameters (k
NaHPO−4
d , k
NaH2PO4
d , k
CaH2PO
+
4
d , k
CaAlb
d , and N
c
PO4
) have a small or negligible
impact on model results.
To determine the overall impact of a given parameter on the predicted values of [Ca2+]p,
[PO4]p, [PTH]p, [D3]p, and [FGF]p, we then calculated the sum of the squares of the fractional
change in these 5 concentrations following a 4-fold increase and a 4-fold decrease in the
value of that parameter. The parameter with the largest overall impact on the 5 steady-
state plasma concentrations is kCapf , followed by, in decreasing order of importance, k
Ca
fp , kfet,
kCaHPO4d , k
PO4
pf , and k
PO4
fp . The parameters k
NaHPO−4
d , k
NaH2PO4
d , kpc, kcp, k
CaH2PO
+
4
d , N
c
PO4
,
and kCaAlbd have the lowest influence on all concentrations.
3 Experimental Measurements
We used samples from previous experiments [32] to measure the PO4 content of mouse skele-
ton. In brief, C57BL/6 mice were housed in 12/12 light/dark conditions and fed a standard
laboratory chow (Kliba Nafnag TS3242; KLIBA) with free access to food and water. Mice
were deeply anesthesized, and their skeleton was cleaned and reduced to ashes. Phosphate
content was determined using the phosphomolybdate method. Animal experiments were
performed according to the Swiss guidelines for animal care and were approved by the ad
hoc Veterinarian State Committee.
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4 Results
4.1 Experimental Results
Using the experimental approach previously described [32], we measured the amount of bone
PO4 in C57BL/6 male and female mice (weighing ∼20g) and extrapolated our results to rats.
The phosphate content in skeleton was 3.77 ± 0.09 (SE) mmol PO4 in male mice (n = 5)
and 3.68 ± 0.14 (SE) mmol PO4 in female mice (n = 5), that is, 0.017 g PO4/g body weight.
Assuming the same ratio in rats, the amount of PO4 in the skeleton of a 300g rat was
calculated as 5.1 g, or 54 mmol. Assuming that the PO4 content in the rapidly exchangeable
pool of bone represents 1-1.5% of that in total bone, as is the case for Ca [61], the amount
of PO4 in the rapid pool of bone was estimated to lie between 0.5 and 0.8 mmol.
4.2 Model validation
Base-case model predictions are summarized in Table 8. The steady-state plasma concentra-
tions of Ca2+, PO4, PTH, vitamin D3, and FGF23 are well within the experimental range.
To test the robustness and relevance of the model, we first compared its predictions with the
results of several experimental studies.
4.2.1 Primary Hyperparathyroidim
Jaeger et al. [39] developed an experimental model of primary hyperparathyroidism in the
rat. Sprague-Dawley rats (weighing 215-295 g) were either parathyroidectomized (PTX) or
thyroparathyroidectomized (TPTX) and subsequently infused with PTH via mini-pumps at
varying doses. The highest dose yielded a 3.5-fold increase in the plasma concentration of
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PTH ([PTH]p). At that dose, the plasma concentration of Ca
2+ ([Ca2+]p) was 50% higher
than its control value; conversely, that of PO4 ([PO4]p) was reduced by 35%, since PTH
inhibits PO4 reabsorption in kidney. Additionally, vitamin D3 levels were increased 3-fold.
We simulated this experiment by increasing the coefficient of PTH production (k
PTHg
prod ) until
[PTH]p reached 3.5 times its basal value. As shown in Table 9, model predictions fit the
experimental data of Jaeger et al. well: [Ca2+]p is predicted to increase by 60%, [PO4]p to
decrease by 35%, and the plasma concentration of vitamin D3 ([D3]p) to increase 4-fold.
4.2.2 Thyroparathyroidectomy
Saito and coworkers measured [Ca2+]p, [PO4]p, and the plasma concentration of FGF23
([FGF23]p) in normal and TPTX male Sprague-Dawley rats weighing 180-200 g [70]. Rizzoli
and coworkers [67, 68] also studied the effect of thyroparathyroidectomy on [Ca2+]p and
[PO4]p in female Wistar rats (∼ 150 g). To simulate TPTX, we abolished the production
of PTH (k
PTHg
prod was set to 0) and computed steady-state concentrations and fluxes. Table
9 shows good agreement between model and experimental results: In TPTX rats, [Ca2+]p
is predicted to decrease by 50% relative to sham (vs. 30-50% experimentally), [PO4]p to
increase by 25% (vs. 40-70%) and [FGF23]p to decrease by 70% (vs. 78%). Moreover, Rizzoli
et al. observed that the intestinal absorption of PO4 decreased by 16% (from 68% in normal
rats to 57% in TPTX rats) [67], and that the intestinal absorption and bone resorption of
Ca were respectively reduced by ∼ 30 and 50% [68]. Similarly, our model predicts that
PO4 absorption is reduced by 22% (from 53% in normal rats to 41% in TPTX rats), Ca
absorption by 40%, and Ca resorption by 60%.
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4.2.3 FGF23 deficiency
Shimada et al. investigated the impact of FGF23 ablation in mice [74]. We simulated this
scenario (denoted FGF23 KO) by setting the coefficient of FGF23 production (kFGFprod ) and
the initial plasma FGF23 concentration to zero. Both the experimental study and the model
found that [D3]p increased significantly in KO mice, relative to sham, whereas [Ca
2+]p did
not (Table 9). Finally, the observed increase in [PO4]p (30 %) was similar to that predicted
by the model (38%).
4.2.4 Intravenous injection of PO4
We then validated our model against the experimental data of Thomas et al. [80], who infused
rats with 0.5 mmol Na2HPO4/NaH2PO4 over 2-3 minutes. To simulate an intravenous
injection of PO4, we increased [PO4]p by a factor 2 over 10 minutes. GFR was varied as in
the experimental study. As illustrated in Figure 2, the model reproduces well the dynamic
evolution of [PO4]p (panel A) and [Ca
2+]p (panel C). The amount of Ca that is not bound
to phosphate drops by 20% immediately after the injection and does not return to its initial
value after 6 hours; this decrease is due to the precipitation of Ca and PO4 in plasma. In
response to the PO4 injection, Thomas et al. found that [PTH]p increases rapidly and stays
elevated (panel E). Our model captures the initial rise in [PTH]p but not the subsequent
stabilization. This discrepancy suggests that there may be a delay in the feedback mechanism
by which PO4 stimulates PTH synthesis, that the model presently does not consider.
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4.2.5 PO4 gavage
In the same study [80], another set of rats received the same amount (0.5 mmol) of Na2HPO4/NaH2PO4
by intestinal gavage. As shown in Figure 2, our model adequately reproduces the experi-
mental results for [PO4]p (panel B) and [Ca
2+]p (panel D). In this case too, the predicted
value of [PTH]p returns to its base-case value faster than observed experimentally (panel F),
which supports our hypothesis of a delay in the feedback mechanism described above.
4.2.6 Acute induced hypercalcemia and hypocalcemia
Gravesen et al. [33] examined the effects of an acute change in [Ca2+]p on [FGF23]p in
male Wistar rats weighing about 250g. They induced hypercalcemia during 60 minutes
by injecting a 25 mM solution containing Ca at a rate of 3mL/h, that is 1.25 µmol/min.
We simulated this scenario by adding an equivalent injection term in the Ca conservation
equation (Eq. 39). Results are shown in Figure 3.
The normalized concentration of PTH (relative to its base-case value) is predicted to
decrease rapidly and to stabilize at 10% of its initial value (panel C) when [Ca2+]p reaches
steady-state (panel A), as also found by Gravesen et al. Both model and experimental results
indicate that [FGF23]p is insensitive to hypercalcemia (results not shown).
In addition, Gravesen et al. investigated the effects of inducing hypocalcemia (by infusing
EGTA) immediately following hypercalcemia. Results are also depicted in Figure 3. When
[Ca2+]p is lowered by 25% (panel B), a 0.3 mM reduction, the model predicts that [PTH]p
quickly increases by a factor of 8 (panel D), then decreases more slowly and stabilizes at
a value that is ∼ 3.5 times its basal value. Gravesen et al. similarly observed a rapid
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5-fold increase in [PTH]p, but no subsequent decrease. Note, however, that the peak-and-
plateau profile predicted by the model is consistent with the experimental findings of Fox [28]
who used a similar protocol. The reason for these different experimental behaviors remains
unclear. In accordance with the findings of Gravesen et al. [33], the model predicts that
lowering [Ca2+]p has no impact on [FGF23]p (results not shown).
4.3 Model Predictions
We then employed the model to examine the effects of variations in GFR and to predict
the impact of primary hyperparathyroidism, primary hypoparathyroidism, and vitamin D3
deficiency on Ca, PO4, and their regulating hormones.
4.3.1 Impact of GFR
We investigated the effects of isolated changes in GFR, and did not account for other changes
in renal function; thus the scenario in which we reduced GFR does not simulate chronic kid-
ney disease per se. As shown in Figure 4, the model predicts that a 25% increase or decrease
in GFR, relative to its base-case value, has a negligible impact on [Ca2+]p, whereas it lowers
or raises [PO4]p by 5% (panel A). Owing to feedback mechanisms, [PTH]p and [FGF23]p vary
by the same factor as [PO4]p. Since PO4, PTH, and FGF23 exert counterbalancing effects
on vitamin D3 synthesis and degradation, [D3]p is barely affected by changes in GFR (panel
B).
Following a decrease in GFR, the increases in [PO4]p, [PTH]p, and [FGF23]p reduce PO4
reabsorption, thereby counteracting the decrease in the filtered load of PO4; by contrast,
the increase in [PTH]p enhances Ca
2+ reabsorption. As a result, a 25% variation in GFR
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is predicted to elicit a comparable 25% variation in the urinary excretion of Ca, but only a
5-7.5% variation in that of PO4 (panels C-D).
4.3.2 Primary hyperparathyroidism
Primary hyperparathyroidism was simulated by increasing the base-case PTH synthesis rate
(k
PTHg
prod ) by a factor ranging from 1 to 300. Shown in Figure 5 are the predicted steady-state
values of [Ca2+]p and [PO4]p (panel A), [PTH]p, [D3]p, and [FGF23]p (panel B), as well as the
urinary excretion, intestinal absorption, Ca and PO4 fluxes into bone and bone resorption
of Ca (Panel C) and PO4 (Panel D), as a function of the normalized k
PTHg
prod (i.e., relative to
its base-case value).
We focus below on the behavior of [FGF23]p as well as PO4 fluxes, as these were not in-
cluded in the previous model [32]. Hyperparathyroidism raises [D3]p (which per se stimulates
FGF23 production), and reduces [PO4]p (a decrease which per se reduces FGF23 produc-
tion). The former effect predominates, so that [FGF23]p is predicted to increase with k
PTHg
prod .
When the rate of PTH synthesis is increased beyond a factor of 50, [FGF23]p stabilizes at
a value that is 36% above baseline. Indeed, the effects of vitamin D3 on FGF23 production
are assumed to reach a saturation point (Eq.41).
The intestinal absorption of PO4 increases with increasing k
PTHg
prod (Panel D), as a conse-
quence of the [D3]p elevation. Similarly, the urinary excretion of PO4 increases with k
PTHg
prod ,
in part as a direct effect of higher PTH levels, but more importantly as a result of the rise in
FGF23 concentration. Thus, it increases less steeply as a function of k
PTHg
prod when [FGF23]p
begins to stabilize. As PO4 urinary losses increase, PO4 storage in bone conversely dimin-
ishes.
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Likewise, the intestinal absorption of Ca increases with increasing k
PTHg
prod . The urinary
excretion of Ca2+ is predicted to increase monotonically with the rate of PTH synthesis, at
a rate that decreases with increasing k
PTHg
prod . Our model suggests that when k
PTHg
prod is ≤ 100
times its baseline value, the effects of CaSR (which enhances Ca2+ excretion) predominate
over those of PTH and vitamin D3 (which diminish Ca
2+ excretion), which explains the
rapid increase in urinary excretion. For higher degrees of hyperparathyroidism (a ≥ 100-
fold increase in k
PTHg
prod ), the relative contributions of PTH and vitamin D3 become more
important as [Ca2+]p (and therefore the effects of CaSR) reaches a plateau value.
The Ca flux into bone and Ca resorption are both predicted to increase with increasing
k
PTHg
prod and to reach a maximum value that is ∼ 1.6 and 1.75 times their basal value, respec-
tively. Since the resorption of Ca increases more than the rate at which it enters the deep
pool, the net flux of Ca into bone becomes negative as the degree of hyperparathyroidism
increases. The predicted loss of PO4 and Ca from bone may partly explain why bone volume
is lower during primary-hyperparathyroidism.
4.3.3 Primary hypoparathyroidism
To simulate primary hypoparathyroidism, we conversely decreased k
PTHg
prod from its base-case
value to zero. Results are depicted in Figure 6. As PTH synthesis diminishes, vitamin D3
and FGF23 levels are predicted to decrease as well (by about 70 % in the absence of PTH,
Panel B), as expected since PTH enhances the synthesis of vitamin D3, and the latter in
turn activates FGF23 production. The decrease in [D3]p reduces the intestinal absorption of
Ca and PO4 (respectively by -40% and -20% in the absence of PTH, Panels C and D). Bone
resorption also diminishes (by -70% for both Ca and PO4, in the absence of PTH) due to
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the reduction in [PTH]p and [D3]p.
Whereas [Ca2+]p decreases monotonically with decreasing k
PTHg
prod , [PO4]p increases until
k
PTHg
prod is decreased by ≤ 90 %, and decreases beyond this value. The increase in [PO4]p
for small decreases in k
PTHg
prod can be explained by the rapid drop in PO4 urinary excretion
compared to other fluxes, especially intestinal PO4 absorption. As k
PTHg
prod further decreases,
intestinal absorption decreases more rapidly, and [PO4]p begins to fall. In the absence of
PTH, [PO4]p is predicted to be 25% higher than its base-case value. In contrast, [Ca
2+]p is
45% below its base-case value.
Note that the profile of urinary PO4 excretion closely mimics that of [FGF23]p. This
reflects our assumption that the impact of FGF23 on PO4 reabsorption along the nephron
is higher than that of PTH (Eqs. 21 and 23).
4.3.4 Vitamin D3 deficiency
To simulate the effects of vitamin D3 deficiency, we decreased the concentration of its precur-
sor, namely [Dinact3 ]p, by a factor ranging from 1 to 100. Results are shown in Figure 7. As
previously described [32], [D3]p does not fall substantially until [D
inact
3 ]p reaches about 10 %
of its base-case value, owing to compensating effects: the decrease in Ca absorption and thus
in [Ca2+]p, combined with the increase in the plasma concentration of PTH (the synthesis of
which is inhibited by vitamin D3), stimulate CYP27B1, thereby partially counteracting the
decrease in [Dinact3 ]p.
Since vitamin D3 is the main regulator of FGF23, the predicted profile of [FGF23]p
mimics that of [D3]p. Our results suggest that [PO4]p slightly increases until [D
inact
3 ]p reaches
∼ 30% of its base-case value, as a result of the significant increase in PO4 reabsorption in
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the proximal tubule (itself a consequence of lower [FGF23]p). Even though the inhibitory
effects of PTH on PO4 reabsorption become more significant, they are not enough to reduce
plasma PO4 levels. When [D
inact
3 ]p is divided by a factor of 5 or more, [D3]p begins to
fall significantly (panel B), and [PO4]p starts to decrease, owing to the large reduction in
intestinal PO4 absorption as well as bone resorption (-25% and - 45% relative to baseline,
respectively, when [Dinact3 ]p = 0). Note that bone resorption is regulated predominantly by
vitamin D3, and to a lesser extent by PTH. Up to the point where [D
inact
3 ]p is divided by 10,
bone resorption increases in parallel with [PTH]p. When [D3]p starts decreasing markedly,
bone resorption diminishes as well. In the absence of vitamin D3, Ca and PO4 resorption is
45% and 35% below baseline, respectively.
In contrast with PO4, the plasma levels of Ca
2+ closely follow those of vitamin D3. The
Ca2+ urinary excretion profile is noteworthy (panel C). Ca2+ urinary excretion is predicted to
decrease until [Dinact3 ]p is halved, then to rise until [D
inact
3 ]p is divided by 10, and finally to drop
substantially. Note that PTH has been shown to inhibit Ca2+ reabsorption in the proximal
tubule [2, 59], whereas it stimulates Ca2+ reabsorption in the thick ascending limb, the distal
convoluted tubule, and the connecting tubule. Our model predicts that for small increases
in [PTH]p, the latter effects are dominant, hence the decrease in Ca
2+ urinary excretion.
However, as [PTH]p increases further, our results suggests that its inhibitory effects in the
proximal tubule prevail over its stimulating effects downstream. As [D3]p nears zero, the
predicted reduction in Ca2+ urinary excretion reflects the significant reduction in the filtered
load, which decreases in parallel with [Ca2+]p (panel A), thus more than compensating the
hormonal effects of PTH and vitamin D3.
Page 31
4.3.5 Oncogenic osteomalacia
Oncogenic osteomalacia, also known as tumor induced osteomalacia (TIO), is due to a
mesenchymal tumor that secretes FGF23, thereby inducing major hypophosphatemia, re-
nal PO4 losses, severe vitamin D3 deficiency [72], as well as heavy bone demineralization
[20, 22, 31, 72]. In humans, the impact of TIO on plasma Ca differs between studies: [Ca2+]p
remained stable in one study [31] but decreased from 1.3 to 1.1 mM in another [20]. Both
groups observed a slight increase in [PTH]p above the normal range. Gore et al. also reported
that fractional PO4 urinary excretion was 40%, and that fractional Ca intestinal absorption
was reduced by 50% [31].
To our knowledge, the impact of high FGF23 synthesis on Ca and PO4 homeostasis
in the rat has not been investigated. To simulate this situation, we added to the FGF23
conservation equation (Eq. 40) an injection term (kFGFinject) that was progressively increased
until the plasma concentration of Ca, PO4, PTH, and vitamin D3 reached saturating values
(i.e., did not vary anymore with kFGFinject).
In accordance with experimental observations in humans, our model predicts that a large
increase in the circulating levels of FGF23 significantly lowers [PO4]p and [D3]p (by 50% and
88%, respectively, at saturation). In addition, at saturation, fractional PO4 urinary excretion
is 40%, and fractional Ca intestinal absorption is reduced by 45%. However, in contrast with
experimental observations, the model predicts a decrease in [Ca2+]p and [PTH]p (by 40% and
28%, respectively, at saturation). Note that the predicted decrease in [Ca2+]p stems from
that in [PTH]p.
Since PO4 activates PTH synthesis, we then examined the impact of this regulation on
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our model results. In the limiting case when the effects of PO4 change on PTH production
were abolished, the model predicted that [PTH]p increased with k
FGF
inject, and [Ca
2+]p remained
approximately stable. [D3]p decreased less than previously but remained below the normal
range. These results suggest that the discrepancy described above could stem, at least partly,
from differences in the contribution of PO4 to the rate of PTH synthesis between rats and
patients with TIO.
It should also be noted that patients with TIO are treated with vitamin D3 and PO4
supplements so as reduce Ca and PO4 bone loss [20, 22, 31], whereas the simulations above
did not account for these treatments. When we simulated TIO in conjunction with the ad-
ministration of vitamin D3 (based on patient treatment, we set k
D3
inject = 3 µg/day), [Ca
2+]p
decreased less (by 30 %), and [PO4]p was reduced by 40% (compared to 50% without treat-
ment). As a result, PTH levels were increased above normal levels, as observed in patients.
We then simulated PO4 supplementation by increasing the daily PO4 intake by a factor
of 4, in addition to the vitamin D3 treatment. In this scenario, [PO4]p and [Ca
2+]p were
comparable to control levels and PTH was 28% above its base-case value. These results
suggest that the treatments with vitamin D3 and PO4 may explain in part the observed rise
in [PTH]p in patients with TIO. Note that our model predicts that above a certain threshold
of vitamin D3 and/or ingested PO4, hypercalcemia may ensue, thereby increasing the risk
of calcifications.
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5 Discussion
Our model of calcium and phosphate homeostasis describes Ca and PO4 exchanges between
the intestine, plasma, the kidneys, two bone pools, and the intracellular compartment in the
case of PO4. It accounts for the regulation of these exchanges by PTH, vitamin D3, as well
as FGF23. The relatively recent discovery of the latter means that FGF23 was ignored in
previous homeostasis models [18, 61, 66].
We validated the model by comparing its predictions with experimental data under sev-
eral conditions. Our results were in good agreement with observations in many scenarios,
such as primary hyperparathyroidism [39], parathyroidectomy [68, 70, 86], PO4 infusion and
gavage [80], together with acute hypercalcemia and hypocalcemia [33] (Figs. 2, 3, and 5).
There were nonetheless some discrepancies between predicted and measured PTH concen-
trations (a) in one of two studies of hypocalcemia (see above), (b) in FGF23 knock-out mice,
and (c) following PO4 loading, as discussed below.
5.1 Coupling between Ca and PO4 homeostasis
To our knowledge, our model is the first one to include the formation of CaPO4 complexes and
calciprotein particles (Eqs. 15-16). Our results suggest that the rapid decrease in plasma Ca
levels observed by Thomas et al. [80] after an intravenous PO4 infusion stems predominantly
from the formation of CaPO4 complexes, not from Ca storage in bone or from urinary Ca
2+
losses. In addition, Thomas et al. found that only 50% of the injected amount of PO4 (500
µmol) was recovered in urine 6 hours after the infusion. Our simulations indicate that 10
minutes after the injection, about 90% of the injected PO4 is in the rapidly exchangeable
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pool in bone (450 µmol), whereas less than 10% is excreted in urine. Subsequently, PO4 is
progressively stored in the intracellular pool (200 µmol 6 hours after the injection), while
only a small amount is incorporated into deep bone (45 µmol 6 hours after the injection).
Finally, our model predicts that about 40% of PO4 is recovered in urine 6 hours after the
injection. Note that since very little is known regarding the hormonal regulation of PO4
fluxes between plasma and the intracellular pool, we assumed that they follow first-order
kinetics.
Thomas et al. [80] also observed a sustained increase in [PTH]p following the PO4 infu-
sion, whereas our model predicts a peak-and-plateau behavior (Fig. 2), owing to the feedback
effects of PO4 on PTH synthesis. Note that even though [Ca
2+]p is reduced by 0.5 mM, this
decrease in itself is not sufficient to maintain [PTH]p about 10 times above its basal value
[28]. This discrepancy suggests that there may be a delay in the regulation of PTH synthesis
by PO4, such that a decrease in [PO4]p may not immediately reduce PTH production.
Whereas a rapid infusion of PO4 significantly reduces [Ca
2+]p, our model predicts that
a rapid infusion of Ca2+ has little impact on [PO4]p. Our simulations suggest that a 30%
increase in [Ca2+]p (resulting from a 9.5 µmol Ca injection) reduces [PO4]p by 1%. According
to our computations, one minute after the injection, 1 µmol Ca has been incorporated in the
rapidly exchangeable pool of bone, and the rest is in plasma, either in the form of Ca2+ (4
µmol), or bound to albumin (4 µmol) or PO4 (0.35 µmol), or present in calciprotein particles.
Ten minutes after the injection, 8 µmol of the injected Ca are in the rapid pool, 0.6 µmol
have been excreted in urine, and the remainder is still bound to plasma proteins. The full
amount of injected Ca is recovered in urine in ∼ 200 minutes. The model predicts that the
formation of CaPO4 complexes is limited by the rapid binding of Ca to albumin.
Page 35
5.2 Impact of hormonal regulations
In both primary hypoparathyroidism and vitamin D3 deficiency, our model suggests that the
Ca and PO4 homeostatic systems are robust enough to handle significant (up to 50%) per-
turbations in the rate of PTH synthesis and in the concentration of the vitamin D3 precursor
([Dinact3 ]p), respectively (Figs. 6-7). Interestingly, the model predicts that [PO4]p does not
vary monotonically with the rate of PTH synthesis or with [Dinact3 ]p, owing to counteracting
effects and negative feedback loops. Partly as a consequence of this, our results suggest that
large perturbations (≥ 90%) have a greater impact on Ca than on PO4: in the absence of
PTH, [Ca2+]p is 45% below its baseline value, whereas [PO4]p is 25% above baseline (Fig. 6A).
When [Dinact3 ]p is set to zero, [Ca
2+]p and [PO4]p are respectively 40% and 15% below baseline
(Fig. 7A). The model yields a similar trend when we simulate the full inhibition of CYP24A1
(the enzyme that catalyzes the degradation of vitamin D3), mimicking a condition known in
humans as infantile hypercalcemia. In this scenario, [D3]p is predicted to increase 8.7-fold
(vs. 9 in Ref. [77]), and [Ca2+]p is 55% above baseline (owing to enhanced intestinal absorp-
tion as well as bone resorption), whereas [PO4]p is 20% below baseline (because of the 50%
increase in [FGF23]p, which stimulates the urinary excretion of PO4). In agreement with
experimental observations, the model also predicts that the subsequent reduction in PTH
levels, in addition to the higher filtered load of Ca2+, generates significant hypercalciuria
[21, 77].
Whether PTH exerts direct effects on FGF23 remains unclear [45, 55]. In the present
model, we assumed that PTH does not, per se, modulate FGF23 synthesis. Nevertheless, our
Page 36
model predicts that PTH variations have a significant impact on FGF23. In our simulations
of primary hyperparathyroidism, when [PTH]p was increased 3.5-fold (relative to its base-
case value), [FGF23]p was predicted to increase by 40%, owing to PTH-induced elevations
in the plasma concentrations of vitamin D3. PTH also reduces plasma PO4 levels, which
per se decreases FGF23 production, but these counteracting effects are not sufficient to
counterbalance the stimulation exerted by vitamin D3. Note that in turn, the increase in
FGF23 synthesis acts to limit the increase in [D3]p.
5.3 Model Limitations
The regulation of PO4 homeostasis has not been as thoroughly investigated as that of Ca. We
therefore had to estimate a large number of parameters, as shown in Table 2. For instance,
the amount of PO4 in the intracellular compartment in rats is not known, to our knowledge.
The dynamics and hormonal regulation of PO4 exchanges between plasma and cells, and
plasma and bone, remain to be characterized. Quantitative data on the binding of PO4 to
proteins are also scarce.
In addition, the model requires specification of kinetic constants related to the formation
of Na-PO4 species, Ca-PO4 species, and Ca-PO4-fetuin A complexes. Whereas the equi-
librium constants of these reactions can easily be found in chemical handbooks, we were
not able to obtain separate estimates of the formation and dissociation rates; we therefore
assumed a constant dissociation rate of 105 s−1. However, many external factors are known
to affect association and dissociation rates, such as pH, the concentration of reactants, and
temperature [52, 83].
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As a simplifying assumption, the plasma concentration of albumin is taken to be constant
in the current model. Several factors affect plasma albumin levels and ultimately [Ca2+]p. In
diabetic patients, albumin levels are decreased because of low insulin. Fasting, liver disease,
nephrotic syndrome, and cardiac insufficiency are other conditions that affect circulating al-
bumin [58]. Accounting for all the underlying mechanisms is beyond the scope of this model.
Nevertheless, albumin levels could be modified when simulating specific scenarios.
In summary, we have developed the first mathematical model of calcium and phosphate
homeostasis in the rat that includes the major phosphocalciotropic hormones, namely PTH,
vitamin D3, and FGF23. The model adequately reproduces experimental findings under
different conditions and can be used to predict the impact of hormonal disturbances on Ca
and PO4 balance.
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Figure Legends
Figure 1 – Left: regulation of plasma Ca levels by PTH and vitamin D3. Right: regulation
of plasma PO4 levels by PTH, vitamin D3, and FGF23.
Figure 2 – Impact of PO4 intravenous infusion and gavage. Model predictions (solid lines)
are compared with the experimental data (open circles) in Ref. [80]. PO∗4 denotes the sum of
PO4 and NaPO4 complexes; Ca
∗ denotes the sum of Ca2+ and Ca-plasma protein complexes.
Left panels: PO4 intravenous infusion. Right panels: PO4 gavage. Panels A-B: plasma
concentration of PO∗4 as a function of time. Panels C-D: normalized (relative to baseline)
plasma concentration of Ca∗ as a function of time. Panels E-F: normalized (relative to
baseline) plasma concentration of PTH.
Figure 3 – Impact of hyper- or hypocalcemia. Model predictions (solid lines) are compared
with the experimental data (open circles) in Ref. [33]. Left panels: Ca intravenous infusion.
Right panels: Ca intravenous infusion followed by EGTA infusion. Panels A-B: normalized
[Ca2+]p as a function of time. Panels C-D: normalized [PTH]p as a function of time.
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Figure 4 – Predicted effects of a 25% decrease and increase in the glomerular filtration rate
(GFR). Results are shown at steady-state and relative to baseline. Panel A: normalized
Ca2+ and PO4 plasma concentrations. Panel B: normalized vitamin D3, FGF23, and PTH
plasma concentrations. Panel C: normalized Ca2+ urinary excretion. Panel D: normalized
PO4 urinary excretion.
Figure 5 – Impact of primary hyperparathyroidism. Results are shown at steady-state, as
a function of the normalized (relative to baseline) rate of PTH synthesis, k
PTHg
prod . Panel A:
normalized Ca2+ and PO4 plasma concentrations. Panel B: normalized PTH, vitamin D3,
and FGF23 plasma concentrations. Panel C: normalized Ca2+ fluxes. Panel D: normalized
PO4 fluxes.
Figure 6 – Impact of hypoparathyroidism. Results are shown at steady-state, as a function
of the normalized k
PTHg
prod . Panel A: normalized Ca
2+ and PO4 plasma concentrations. Panel
B: normalized PTH, vitamin D3, and FGF23 plasma concentrations. Panel C: normalized
Ca2+ fluxes. Panel D: normalized PO4 fluxes.
Figure 7 – Impact of vitamin D3 deficiency. Results are shown at steady-state, as a function
of the normalized plasma concentration of the vitamin D3 precursor, [D
inact
3 ]p. Panel A:
normalized Ca2+ and PO4 plasma concentrations. Panel B: normalized PTH, vitamin D3,
and FGF23 plasma concentrations. Panel C: normalized Ca2+ fluxes. Panel D: normalized
PO4 fluxes.
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Table 1 – Ca and PO4 Complex Parameters
Reaction Parameter Symbol Value Source
Calcium-albumin
CaAlb formation rate constant kCaAlbf 190.2 mM
−1.min−1 [26]
CaAlb dissociation rate constant kCaAlbd 1666.7 min
−1 Estimated
Concentration of albumin in plasma [Albtot]p 0.36 mM [88]
Sodium-phosphate
NaHPO−4 formation rate constant k
NaHPO−4
f 7.84 mM
−1.min−1 [57]
NaHPO−4 dissociation rate constant k
NaHPO−4
d 1666.7 min
−1 Estimated
NaH2PO4 formation rate constant k
NaH2PO4
f 4.9 mM
−1.min−1 [57]
NaH2PO4 dissociation rate constant k
NaH2PO4
d 1666.7 min
−1 Estimated
Sodium plasma concentration [Na+]p 142 mM [52]
Calcium-Phosphate precipitation
CaHPO4 formation rate constant k
CaHPO4
f 1137.26 mM
−1.min−1 [83]
CaHPO4 dissociation rate constant k
CaHPO4
d 1666.7 min
−1 Estimated
CaH2PO
+
4 formation rate constant k
CaH2PO
+
4
f 52.94 mM
−1.min−1 [83]
CaH2PO
+
4 dissociation rate constant k
CaH2PO
+
4
d 1666.7 min
−1 Estimated
Fetuin-A binding to CaHPO4 and CaH2PO
+
4 kfetA 0.3 min
−1 Fitted from [80]
CPP degradation rate constant kCPPdeg 3 min
−1 [38]
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Table 2 – Phosphate Homeostasis Parameters
Organ Parameter Symbol Value Source
Intestine
Phosphate intake IPO4 1.55 µmol.min
−1 [78]
Sensitivity of PO4 absorption to vitamin D3 K
D3
abs 640 pM Estimated
Kidney
Minimal fractional reabsorption of PO4 in the PT λ0PT 0.55 [63]
Stimulation of PO4 reabsorption in PT by PTH δmaxPTH 0.10 Estimated
Sensitivity of PO4 reabsorption in PT to PTH KPTHPT 20 pM Estimated
Stimulation of PO4 reabsorption in PT by FGF23 δmaxFGF 0.20 Estimated
Sensitivity of PO4 reabsorption in PT to FGF23 KFGFPT 20 pM Estimated
Stimulation of PO4 reabsorption in PT by PO4 δmaxPO4 0.10 Estimated
Sensitivity of PO4 reabsorption in PT to PO4 K
PO4
PT 1.6 mM [87]
Fractional reabsorption of PO4 in the DCT λ
PO4
DCT 0.1 [63]
Slow Bone
rate constant of PO4 flux into bone γ
PO4
in 2.75 × 10−4 min−1 [61]
Minimal resorption rate Γminres,PO4 0.03 µmol.min
−1 [61]
Maximal resorption rate δmaxres,PO4 0.20 µmol.min
−1 [61]
Stimulation of resorption by vitamin D3 K
D3
res 600 pM Estimated
Stimulation of resorption by PTH KPTHres 6.12 pM Estimated
Fast Bone
Rate constant of PO4 transfer from plasma to fast bone pool k
PO4
pf 13.5 min
−1 Fitted from [80]
Rate constant of PO4 transfer from fast bone pool to plasma k
PO4
fp 0.25 min
−1 Fitted from [80]
Intracellular Phosphate
Total quantity of PO4 in cells NcPO4 3 mmol Estimated
Rate constant of PO4 transfer from plasma to intracellular pool kpc 0.19 min−1 Fitted from [80]
Rate constant of PO4 transfer from intracellular pool to plasma kcp 0.001 min−1 Fitted from [80]
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Table 3 – Calcium Homeostasis Parameters
Organ Parameter Symbol Value Source
Intestine
Calcium intake ICa 2.2
∗ µmol.min−1 [19, 51]
Sensitivity of Ca absorption to vitamin D3 K
D3
abs 640
∗ pM Estimated
Kidney
Glomerular filtration rate GFR 2 mL.min−1 [89]
Minimal fractional reabsorption of Ca2+ in the PT λ0PT 0.64
∗ [6, 60]
Stimulation of Ca2+ reabsorption in PT by PTH δmaxPT 0.01
∗ Estimated
Sensitivity of Ca2+ reabsorption in PT to PTH PTHref 15 pM Estimated
Minimal fractional reabsorption of Ca2+ in the TAL λ0TAL 0.225 [6, 60]
Stimulation of Ca2+ reabsorption in TAL by PTH δmaxPTH 0.0075 Estimated
Sensitivity of Ca2+ reabsorption in TAL to PTH KPTHTAL 4.2
∗ pM Estimated
Stimulation of Ca2+ reabsorption in TAL by CaSR δmaxCaSR 0.0175 Estimated
Sensitivity of Ca2+ reabsorption in TAL to Ca2+ Cref 1.33 mM Estimated
Minimal fractional reabsorption of Ca2+ in the DCT-CNT λ0DCT 0.090
∗ [6, 60]
Stimulation of Ca2+ reabsorption in the DCT-CNT by PTH and vitamin D3 δmaxDCT 0.010
∗ Estimated
Sensitivity of Ca2+ reabsorption in the DCT-CNT to PTH KPTHDCT 6.3
∗ pM Estimated
Sensitivity of Ca2+ reabsorption in the DCT-CNT to vitamin D3 K
D3
DCT 480
∗ pM Estimated
Slow Bone Pool
rate constant of Ca flux into bone γCain 5.5 × 10−4 ∗ min−1 Estimated
Minimal resorption rate Γminres,Ca 0.10
∗ µmol.min−1 [19]
Maximal resorption rate δmaxres,Ca 0.60
∗ µmol.min−1 [19]
Sensitivity of resorption to vitamin D3 K
D3
res 600
∗ pM Estimated
Sensitivity of resorption to PTH KPTHres 6.12
∗ pM Estimated
Fast Bone Pool
Rate constant of Ca2+ transfer from plasma to fast bone pool kCapf 0.44
∗ min−1 Fitted from [80]
Rate constant of Ca2+ transfer from fast bone pool to plasma kCafp 2.34 ×10−3 ∗ min−1 Fitted from [80]
Asterisks denote values that differ from those used in our previous model [32].
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Table 4 – PTH Parameters
Parameter Symbol Value Source
PTHg synthesis rate k
PTHg
prod 41.9 µmol.min
−1 Fitted from [33]
Sensitivity of PTHg synthesis to vitamin D3 K
D3
PTH 1.2 nM Estimated
Sensitivity of PTHg production to PO4 K
PO4
PTH 2.4 mM Estimated
PTHg degradation rate constant k
PTHg
deg 0.035 min
−1 [1]
Rate constant for maximal PTHg secretion β
PTHg
exo 0.059 min−1 Fitted from [28]
Rate constant for maximal inhibition of PTHg secretion by Ca
2+ γ
PTHg
exo 0.058 min−1 Fitted from [28, 33]
Binding of Ca2+ to CaSR KCa 1.16 mM [28]
nexo1 100 [75]
nexo2 30 Fitted from [33]
R 1.1 mM [75]
ρexo 10 mM
−1 [75]
PTHp degradation rate constant k
PTHp
deg 1.3 min
−1 [1]
Volume of parathyroid glands Vc 0.1 µL [35]
Volume of plasma volume Vp 10 mL [48]
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Table 5 – Vitamin D3 Parameters
Parameter Symbol Value Source
Rate constant for minimum production of vitamin D3 k
min
conv 8.8× 10−6 min−1 [81]
Maximal increase in vitamin D3 production rate δ
max
conv 1.4× 10−4 min−1 [81]
Plasma concentration of Dinact3 [D
inact
3 ]p 25 nM [28]
Sensitivity of vitamin D3 production to PTH K
PTH
conv 15.7 pM Estimated
Time delay for PTH effects on vitamin D3 production τ 240 min [47]
Sensitivity of vitamin D3 production to Ca
2+ KCaconv 3.3 mM Estimated
Sensitivity of vitamin D3 production to vitamin D3 K
D3
conv 333 pM Estimated
Sensitivity of vitamin D3 production to PO4 K
PO4
conv 5 mM Estimated
Sensitivity of vitamin D3 production to FGF23 K
FGF
conv 50 pM Estimated
Rate constant for vitamin D3 degradation k
D3
deg 0.001 min
−1 [3, 23, 40]
Inhibition of vitamin D3 degradation by PTH γ
PTH
D3
1 pM−1 Estimated
Activation of vitamin D3 degradation by FGF23 γ
FGF
D3
0.13 pM−1 Estimated
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Table 6 – FGF23 Parameters
Parameter Symbol Value Source
Minimal rate of FGF23 synthesis kFGFprod 6.9 fM.min
−1 Estimated
Maximal activation of FGF23 synthesis δFGFprod 10 Estimated
Sensitivity of FGF23 synthesis to vitamin D3 K
D3
FGF 564 pM [87]
Sensitivity of FGF23 synthesis to PO4 K
PO4
FGF 1.6 mM [87]
FGF23 degradation rate constant kFGFdeg 0.014 min
−1 [87, 44]
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Table 7 – Sensitivity Analysis
Parameter [Ca2+]p (mM) [PO4]p (mM) [PTH]p (pM) [D3]p (pM) [FGF23]p (pM)
base case 1.21 1.50 5.94 536 14.80
kCapf × 0.25 +42% -3% -81% -49% -66%
kCafp × 0.25 -36% -14% +98% +95% +55%
kCaAlbd × 0.25 0% 0% 0% 0% 0%
kPO4pf × 0.25 0% +7% +9% +3% +8%
kPO4fp × 0.25 -2% -30% -34% -12% -31%
kpc × 0.25 0% 0% 0% 0% 0%
kcp × 0.25 -1% -3% -2% -1% -3%
NcPO4 × 0.25 0% 0% 0% 0% 0%
k
NaHPO−4
d × 0.25 -1% -5% -6% -2% -5%
kNaH2PO4d × 0.25 -1% -3% -3% -1% -3%
kCaHPO4d × 0.25 -21% -36% +9% +11% -3%
k
CaH2PO
+
4
d × 0.25 -1% -3% +2% +1% +1%
kfet × 0.25 +5% + 42% -30% -15% -20%
kCapf × 4 -56% -10% +109% +114% +59%
kCafp × 4 +34% 0% -80% -47% -65%
kCaAlbd × 4 0% 0% 0% 0% 0%
kPO4pf × 4 -2% -30% -34% -12% -31%
kPO4fp × 4 0% +7% +9% +3% +8%
kpc × 4 0% -1% -1% 0% -1%
kcp × 4 0% 0% 0% 0% 0%
NcPO4 × 4 0% 0% 0% 0% 0%
k
NaHPO−4
d × 4 0% +5% +6% +2% +5%
kNaH2PO4d × 4 0% +4% +5% +2% +4%
kCaHPO4d × 4 +5% +42% -29% -15% -20%
k
CaH2PO
+
4
d × 4 0% +1% -1% 0% 0%
kfet × 4 -22% -37% +10% +12% -2%
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Table 8 – Baseline Model Predictions.
Species Model Prediction Experimental Range
PO4
[PO4]p (mM) 1.48 0.8-1.6 [70, 80]
Intestinal absorption (µmol.min−1) 0.82 0.2-1.1 [78]
Fractional PO4 absorption (%) 53 30-80 [67]
PO4 flux into bone (µmol.min−1) 0.22
PO4 resorption (µmol.min−1) 0.12
Net PO4 flux into bone (µmol.min−1) 0.10
Urinary PO4 excretion (µmol.min−1) 0.40 0.03-2 [78]
Fractional PO4 excretion (%) 13.42 10-15
Ca
[Ca2+]p (mM) 1.21 1.1-1.3 [9, 11, 66, 82]
Intestinal Ca absorption (µmol.min−1) 0.98 0.55-1.22 [25, 51]
Fractional Ca absorption (%) 45 40-60 [14, 68]
Ca2+ flux into bone (µmol.min−1) 1.01
Ca2+ resorption (µmol.min−1) 0.40
Net Ca2+ flux into bone (µmol.min−1) 0.61
Urinary Ca2+ excretion (µmol.min−1) 0.039 0.015-0.054 [43, 51, 71, 89]
Fractional Ca2+ excretion (%) 1.62 0-2 [43, 51, 71, 89]
Hormones
[PTH]p (pM) 6.87 1.5-15 [9, 16, 28, 82]
[D3]p (pM) 564.3 80-700 [12, 17, 34, 80]
[FGF23]p (pM) 16.8 11.7-21.1[33, 70, 80]
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Table 9 – Comparison between Model Predictions and Experimental Data
Simulation Variable Model Predictions Experimental Values
PHP1
[Ca2+]p +60% +50%
[PO4]p -35% -35%
[D3]p +300% +200%
TPTX
[Ca2+]p -50% -30-50%
[PO4]p +25% +40-70%
[FGF23]p -70% - 78%
Intestinal PO4 absorption -22% -16%
Intestinal Ca2+ absorption -39% -30%
Ca2+ resorption -60% -50%
FGF23 KO
[Ca2+]p +8% NS
[PO4]p +38% +30%
[PTH]p -58% NS
[D3]p +52% ∼200%
Results for rats with primary hyperparathyroidism (PHP1) [39], thyroparathyroidectomized rats (TPTX)
[67, 70, 86] and mice with FGF23 ablation (FGF23 KO) at day 10 [74].
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